Status:
COMPLETED
NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
Lead Sponsor:
Neos Therapeutics, Inc
Conditions:
Attention Deficit Hyperactivity Disorder (ADHD)
Eligibility:
All Genders
6-12 years
Phase:
PHASE3
Brief Summary
This is a randomized, double-blind, placebo-controlled, parallel group, Phase 3 trial to evaluate the safety and efficacy of NT0102 in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) ...
Eligibility Criteria
Inclusion
- Currently being treated for ADHD
Exclusion
- Other psychiatric diagnoses
- Significant cognitive impairment
- Chronic medical illnesses
- Structural cardiac defects
- Significant abnormal lab tests
- Taking disallowed medications
- Positive drug test
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
87 Patients enrolled
Trial Details
Trial ID
NCT01835548
Start Date
July 1 2013
End Date
July 1 2014
Last Update
January 17 2018
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Florida Clinical Research Center
Bradenton, Florida, United States, 34208
2
Florida Clinical Research Center
Maitland, Florida, United States, 32751
3
Center for Psychiatry and Behavioral Medicine
Las Vegas, Nevada, United States, 89128
4
Duke University
Durham, North Carolina, United States, 27705